Aurobindo Pharma's Curateq Gets CDSCO Nod for Bevacizumab Biosimilar

Curateq Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Ltd, has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) for Bevqolva®, a bevacizumab biosimilar. The authorization, granted under Form CT 23, allows CuraTeQ to manufacture and market Bevqolva® in 100 mg/4mL and 400 mg/16 mL vial presentations from its Hyderabad facility. Bevqolva® is indicated for metastatic carcinoma of the colon or rectum.